GenMark Diagnostics in Carlsbad developed the ePlex multiplex molecular diagnostic platform at its La Place Court campus before joining the Roche Group through a $1.8 billion acquisition in 2021. The ePlex system — now rebranded as the cobas eplex under Roche — integrates nucleic acid extraction, amplification, and eSensor electrochemical detection into a single self-contained cartridge, delivering results that PT clinics refer to when DNA Physical Therapy suspects an infectious rather than musculoskeletal origin for a patient's inflammatory presentation. FDA-cleared panels on the platform cover respiratory pathogens (detecting over 20 viral and bacterial targets), bloodstream infections, and gastrointestinal pathogens, giving hospital laboratories a consolidated syndromic testing solution from a single sample. The Carlsbad campus maintains principal operations for the cobas eplex line, with manufacturing, R&D, and quality-assurance teams continuing at the La Place Court facility under Roche's diagnostics division. Rapid pathogen identification from the cobas eplex guides infection-management decisions across care settings, and home-health agencies coordinating respiratory-symptom response — including Archer Health in Carlsbad — receive those actionable results through partnering hospital lab networks. The platform's digital microfluidic cartridge architecture processes each sample through automated extraction, PCR amplification, and electrochemical detection within approximately 90 minutes, with capacity for 96 tests per eight-hour shift on a single modular tower.